  
Laboratory of  
ecosystem management


# Dealing with toxic impacts in life cycle assessment



  
ÉCOLE POLYTECHNIQUE  
FÉDÉRALE DE LAUSANNE



Olivier Jolliet  
with contributions from David Pennington,  
Pierre Crettaz, Geneviève Perrenoud and  
Simon-Pierre Keller

Industrial ecology - Life Cycle Systems,  
Institute of Environmental Science and Technology,  
Ecole Polytechnique Fédérale de Lausanne (EPFL),  
CH-1015 Lausanne, Switzerland.  
[olivier.jolliet@epfl.ch](mailto:olivier.jolliet@epfl.ch), <http://gecos.epfl.ch/lcsystems>

Portland dose-response workshop, 14 November 2004








Appendix B: Dose Response Workshop  
O. Jolliet Presentation

**ILSI Panel**  
**Severity: Burke et al., 1996**




**Subcategory 1 (Irreversible/life-shortening effects)**

**Subcategory 2 (Maybe reversible/maybe life-shortening)**

**Subcategory 3 (Generally reversible/generally not life-shortening)**

Cancer	Immuno toxicity	Irritation
Reproductive effects	Neurotoxicity	Sensitization
Teratogenic effects	Kidney damage	Reversible acute organ effects (i.e. G1 inflammation)
Acute fatal or acute severe and irreversible effects (i.e. fatal poisoning)	Liver damage	
Mutagenicity	Heart disease	
	Pulmonary (i.e. asthma)	

**Dose - response / potency**  
**SETAC-EU WGIA2**  
(working group on impact assessment)





**Type of indicator**

**Key Advantages**

**Key Issues**

**LCIA application**

Regulatory potency measures, ADIs, RFDs, RFCs	Widely adopted risk assessment	Inconsistent conservatism, adverse risk rather than low-dose risk	Hertwich Huijbregts Goedkopp and Spiersma, partly Hauschild et al.
Slope factors based on benchmark doses, such as $\beta$ ED10	Introduced to provide a consistent basis for low-dose risk response carcinogens and non-carcinogens	Not widely adopted yet while implicit in most measures for non-carcinogenic effects	(Crettaz et al., 2001a, b) 1000 substances
Acute toxicity data, such as LD <sub>50</sub> s and LC <sub>50</sub> s	Widely available data.	Relative acute to chronic importance is unlikely to be consistent across chemical emissions.	Partly used in (Hauschild et al., 1997). Extrapolations acute to chronic data are widely adopted.



**Severity based indicators**  
**SETAC-EU WGIA2**



ÉCOLE POLYTECHNIQUE  
FÉDÉRALE DE LAUSANNE

Type of indicators	Key Advantages	Key Issues	LCIA application
<b>Qualitative indicators</b>			
ILSI classification: Health endpoints allocated to 3 categories (Burke et al., 1996)	Somewhat homogeneous group of health effects with different levels of severity.	3 categories allows rough severity ranking only. Weighting requires value judgement.	Demonstrated by Owens (2000) and adapted by Crettaz et al. (2001b)
<b>Quantitative indicators</b>			
Disability Adjusted Life Years (DALY), based on (Murray and Lopez, 1996), supported by WHO, World Bank	Allows aggregation of mortality and morbidity) on a single cardinal scale.	No final consensus on weighting factors for different health effects. DALY not always possible	(Hofstetter), Eco-indicator '99 (Goedkopp and Spriensma (Crettaz et al. 2001a, b) present data for over 1000 chemicals.
Quality Adjusted Life Years (QALY) (e.g. Rosser, 1987)	(similar to DALY)	(similar to DALY)	not currently used in LCIA but in RA
Years Of Life Lost (YOLL)	aggregation of different mortality effects	Giving the same value to any life year: a value choice not cover non-fatal effects.	key indicator in ExternE-type applications (European Commission, 1999)




**Human toxicity recommendations**  
**A stepwise procedure (SETAC-EU WGIA2)**



ÉCOLE POLYTECHNIQUE  
FÉDÉRALE DE LAUSANNE


<b>1. Toxicological potency indicators such as ED10 as a minimum default</b>
- While methods in their infancy, it is encouraged to take into account relative severity,
--> 2. YOLL      3. DALY/QALY
<b>Key tasks:</b>
<ul style="list-style-type: none"> <li>- Lack of toxicity data</li> <li>- Population density</li> <li>- Aggregation linked to severity authorised by international body</li> </ul>



## Points to be addressed





- How to derive dose-response information for a large number of chemicals (eventually screening and advanced approaches) ?
- Relevance: How to relate the animal endpoint to human endpoints and eventually YLL, YLD ?
- How to make endpoints comparable, using e.g. DALY's ?




## Points to be raised



- Extrapolations chemical with acute, QSAR: shows that restricted !!
- Severity: as soon as impact scores are added, a weighting is performed with equal severity. If all endpoints are kept separate → OK
- Interesting to come to DALY because: upper limit, put into perspective to observed damages
- Always come back to initial goal of comparison → kg equ substance to communicate
- The way it can be used in practice: BMW




 Laboratory of ecosystem management

## EVALUATION from the tumor dose $TD_{50a}$

 ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE


- The  $TD_{50s}$  -  $ED_{10s}$  correlation is relatively high ( $n=37$ ;  $R^2=0.75$ )

**IRIS**



**GOLD**


- Apply to 671 substances with a  $TD_{50a}$  in the CPDB [Gold and Zeiger, 1997]  
==> Slope factors:  $10^{-4} \rightarrow 10^4$  [Risk/ mg/kg-day]: Factor 100 million !

 Laboratory of ecosystem management

## Correlation $ED_{10} - TD_{50}$ data provided for 670 carcinogens

 ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE



**IRIS**







**IRIS**



$ED_{10h} = TD_{50a}/22 ; R^2=0.94$


**Dose-response: 80% variation between databases, against 20% between  $TD_{50}$  and  $ED_{10}$ . Use the best database for  $TD_{50}$ .**









  
Laboratory of ecosystem management


# Compatibility between approaches

  
ÉCOLE POLYTECHNIQUE  
FÉDÉRALE DE LAUSANNE



---


Unit risks versus epidemiologic approaches !

Impacts of particles:



Appendix B: Dose Response Workshop  
O. Jolliet Presentation






The diagram shows the severity of endpoints for non-carcinogens. It is organized into three columns (1, 2, 3) based on the severity of the effect:

1	2	3
Irreversible/ life-shortening effects	May be irreversible/ life-shortening effects	Reversible / not life-shortening effects
Cancer	Immunotoxicity	Irritation
Mutagenicity	Neurotoxicity (*)	Sensitization
Teratogenic effects	Kidney damage	
Reproductive effects	Liver damage	
	Pulmonary disease	
	Heart disease	
<b>100</b>	<b>10</b>	<b>1</b> [Burke et al, 1996]
<b>6 DALY/pers</b>	<b>0.6 DALY/pers</b>	<b>0.06 DALY/pers</b>

## Appendix B: Dose Response Workshop O. Jolliet Presentation



Laboratory of  
ecosystem management


# Cancers severity



ÉCOLE POLYTECHNIQUE  
FÉDÉRALE DE LAUSANNE

Type of Cancer	Disability			Death			Disability + Death $DALY_p = YLD_p + YLL_p$ [yr. lost/inc.]
	W [-]	D [yr. lost/inc.]	$YLD_p = W \cdot D$ [yr lost/inc.]	L [yr. lost]	N [inc.]	$YLL_p = L/N$ [yr. lost/inc.]	
Mouth and oropharynx	0.145	4.3	0.62	3.2E+06	1.1E+06	2.9	3.5
Oesophagus	0.217	1.7	0.37	3.4E+06	3.8E+05	8.9	9.3
Stomach	0.217	2.9	0.63	7.0E+06	1.1E+06	6.5	7.2
Colon and rectum	0.217	3.7	0.80	3.9E+06	9.9E+05	3.9	4.7
Liver	0.239	1.6	0.38	6.3E+06	5.4E+05	11.6	12.0
Pancreas	0.301	1.2	0.37	1.5E+06	1.9E+05	7.9	8.3
Trachea, bronchus, lung	0.146	1.8	0.26	8.3E+06	1.1E+06	7.9	8.2
Melanoma	0.045	4.2	0.19	5.1E+05	1.7E+05	3.1	3.2
Breast	0.069	4.2	0.29	3.8E+06	1.1E+06	3.6	3.9
Cervix uteri	0.066	3.8	0.25	2.7E+06	4.5E+05	6.0	6.2
Corpus uteri	0.066	4.5	0.30	5.8E+05	3.1E+05	1.9	2.2
Ovary	0.081	3.4	0.28	1.3E+06	2.0E+05	6.4	6.7
Prostate	0.113	4.2	0.47	1.1E+06	6.8E+05	1.6	2.1
Bladder	0.085	4.2	0.36	9.8E+05	4.6E+05	2.1	2.5
Lymphomas and myeloma	0.089	3.5	0.31	3.0E+06	4.2E+05	7.2	7.5
Leukemia	0.112	3.1	0.35	4.4E+06	3.1E+05	14.3	14.6
Other cancers*	0.809	n.a.		1.3E+07	1.0E+06	13.0	13.0
<b>Average</b>							6.7

**Due to difficulty to determine human endpoint,  
taken the average for all cancers**



Laboratory of  
ecosystem management

# Severity




ÉCOLE POLYTECHNIQUE  
FÉDÉRALE DE LAUSANNE

**Main challenges:**

- Dose-response for animal → human endpoints**
- No severity = (Implicit) weighting in LCA,  
when summing up accross substances  
assume equal severity !! Not ISO compatible**
- Report death, N°cases, YLL, YLD separately**
- Disability weight optionals, new approaches to  
establish them**

16




Laboratory of  
ecosystem management

## Relationship animal endpoint - human



### Alternatives

- Stay at separate endpoints for animals (Owens)
- Endpoint animals = endpoint humans ? No !
- Start from human evidences and link it back to or use animal dose-response.
  - a) If similar endpoints human-animals = lower uncertainty
  - b) If different endpoints human-animals = high uncertainty in dose-response



Laboratory of  
ecosystem management

## Example carbon tetrachloride



Strong humans evidences	YLL/incidence years	Duration years	Disability weight	YLD	DALY
Cirrhosis	17	7.8	0.33	2.6	19.6
Hepatitis	2.14	0.17	0.20	0.04	2.18

## Some Comments on LCIA for Noncancer Effects

Lorenz Rhomberg, Ph.D.

Gradient Corporation

Cambridge, MA


[lrhomberg@gradientcorp.com](mailto:lrhomberg@gradientcorp.com)

$$IMPACT = \left[ \frac{\text{Pop'n.}}{\text{Exposed}} \right] \times \left[ \frac{\text{Avg.}}{\text{Exposure}} \right] \times \left[ \frac{\text{Risk per}}{\text{person-unit Exposure}} \right]$$

$$\frac{IMPACT}{\text{unit emission}} = \left[ \frac{[\text{Pop'n. Exposed}] \times [\text{Avg. Exposure}]}{\text{unit emission}} \right] \times [\text{Risk per person-unit Exposure}]$$

Risk must be a linear function of Exposure  
(in the range of interest)

Appendix B: Dose Response Workshop  
L. Rhomberg Presentation




## For Noncancer Effects

- Threshold effects; nonlinear dose-response
- Traditional approach focuses on identifying a dose-rate likely to be "safe" (and not on dose-response)


## LCIA Needs for Assessing Noncancer Effects

1. An approach to nonlinear dose-response in humans
2. Estimates of the numbers of people exposed at different levels



Source: SJS Baird *et al.*, SRA, 2000



## Appendix B: Dose Response Workshop L. Rhomberg Presentation





The challenge for exposure analysis:  
to express the population distribution  
of exposure  
(per unit of emissions, without specific times  
and places).

## Appendix B: Dose Response Workshop

### L. Rhomberg Presentation



## Appendix B: Dose Response Workshop L. Rhomberg Presentation



## Appendix B: Dose Response Workshop L. Rhomberg Presentation

